Levosalbutamol Uses, Dosage, Side Effects & Price | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Levosalbutamol
Therapeutic Class: Bronchodilator
Subclass: Short-acting β2-agonist (SABA)
Speciality: Pulmonology
Schedule (India): Schedule H
Route(s): Inhalation (MDI), Nebulisation, Oral
Formulations Available in India:
| Formulation | Strength | Pack Details |
| Metered Dose Inhaler (MDI) | 50 mcg/actuation | 200 doses/canister |
| Nebuliser Solution (Respules) | 0.31 mg/2.5 mL | Single-dose vials |
| Nebuliser Solution (Respules) | 0.63 mg/2.5 mL | Single-dose vials |
| Nebuliser Solution (Respules) | 1.25 mg/2.5 mL | Single-dose vials |
| Syrup | 1 mg/5 mL | 60 mL, 100 mL bottle |
| Tablet | 1 mg | Strip of 10/15 |
| Tablet | 2 mg | Strip of 10/15 |
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
⮞ 1. Acute Bronchospasm (Asthma Exacerbation, COPD Exacerbation, Acute Wheeze)
A) Inhalation via MDI:
| Parameter | Recommendation |
| Starting dose | 1 puff (50 mcg) via MDI with spacer |
| Titration | May repeat 1–2 puffs after 15–20 minutes if inadequate response |
| Usual maintenance dose | 1–2 puffs every 4–6 hours as needed |
| Maximum dose | 2 puffs (100 mcg) per dose; up to 8 puffs/day |
Clinical Notes:
- Always use spacer device for optimal drug delivery
- In acute severe asthma, may use 4–6 puffs initially with spacer, repeated every 20 minutes for first hour
B) Nebulisation:
| Parameter | Recommendation |
| Starting dose | 0.63 mg nebulised over 5–15 minutes |
| Titration | May increase to 1.25 mg based on severity and response |
| Usual maintenance dose | 0.63–1.25 mg every 6–8 hours |
| Maximum dose | 3.75 mg/day in divided doses |
Clinical Notes:
- Use with oxygen-driven nebuliser in acute exacerbations
- Can combine with ipratropium bromide for additive effect in severe cases
⮞ 2. Asthma Maintenance — Reliever (PRN) Therapy
| Parameter | Recommendation |
| Starting dose | 1 puff (50 mcg) MDI as needed |
| Titration | Not applicable for PRN use |
| Usual maintenance dose | 1–2 puffs as needed for symptoms |
| Maximum dose | Should not exceed 8 puffs/day on regular basis |
Clinical Notes:
- Must be used alongside inhaled corticosteroids (ICS) for persistent asthma
- Frequent SABA use (>2 times/week) indicates poor control — reassess and step-up controller therapy
- Single-agent SABA therapy without ICS is not recommended in persistent asthma
⮞ 3. Chronic Bronchospasm — Oral Route (Limited Use)
Oral route is less preferred due to higher systemic adverse effects; use only when inhaled route not feasible.
| Parameter | Recommendation |
| Starting dose | 1 mg twice daily (tablet or syrup equivalent) |
| Titration | May increase based on response and tolerability |
| Usual maintenance dose | 1–2 mg twice to three times daily |
| Maximum dose | 2 mg three times daily (6 mg/day) |
Clinical Notes:
- Reserve for patients unable to use inhaler or nebuliser
- Higher incidence of tremor, palpitations, and hypokalaemia with oral route
Secondary Indications — Adults Only (Off-label, if any)
⮞ Acute Severe Asthma/COPD with Ipratropium Combination Nebulisation — OFF-LABEL (Accepted Practice)
| Parameter | Details |
| Indication | Acute severe bronchospasm unresponsive to SABA alone |
| Dose | Levosalbutamol 1.25 mg + Ipratropium 500 mcg nebulised together |
| Frequency | Every 20 minutes for 3 doses in first hour, then every 4–6 hours |
| Duration | Until acute phase resolved |
| Supervision | Emergency/ICU setting preferred |
| Evidence basis | Indian hospital protocols; widely accepted clinical practice |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
⮞ Acute Bronchospasm / Viral-Induced Wheeze / Asthma Exacerbation
A) Nebulisation (Preferred in young children):
| Age/Weight | Starting Dose | Usual Maintenance | Maximum Dose |
| 6 months – 2 years (<15 kg) | 0.31 mg | 0.31–0.63 mg every 6–8 hours | 1.25 mg/day |
| 2–6 years (15–20 kg) | 0.63 mg | 0.63 mg every 6–8 hours | 1.89 mg/day |
| >6 years (>20 kg) | 0.63–1.25 mg | 0.63–1.25 mg every 6–8 hours | 3.75 mg/day |
Clinical Notes:
- Administer via face mask in children <4 years
- In acute severe exacerbation, may nebulise every 20 minutes for first hour under supervision
- Consider adding nebulised ipratropium if poor response
B) MDI via Spacer with Mask/Mouthpiece:
| Age | Dose | Frequency | Maximum |
| 1–4 years | 1 puff (50 mcg) via spacer + mask | Every 4–6 hours PRN | 4 puffs/day |
| ≥4 years | 1–2 puffs via spacer + mouthpiece | Every 4–6 hours PRN | 8 puffs/day |
Clinical Notes:
- MDI with spacer is as effective as nebulisation and preferred for mild-moderate exacerbations
- Ensure proper technique; reassess at each visit
C) Oral Route (Syrup/Tablets — Limited Use):
| Age | Starting Dose | Usual Maintenance | Maximum |
| 2–6 years | 0.5 mg (2.5 mL syrup) BD | 0.5–1 mg BD–TDS | 3 mg/day |
| 6–12 years | 1 mg BD | 1 mg BD–TDS | 4 mg/day |
| >12 years | 1 mg BD | 1–2 mg BD–TDS | 6 mg/day |
Clinical Notes:
- Oral route only when inhaled route not feasible
- Higher systemic side effects expected
Secondary Indications — Paediatric Doses (Off-label, if any)
⮞ Bronchiolitis in Infants — OFF-LABEL
| Parameter | Details |
| Status | NOT ROUTINELY RECOMMENDED per IAP guidelines |
| If used | 0.31 mg nebulised as therapeutic trial under specialist supervision |
| Evidence | Limited benefit demonstrated; not standard of care |
| Supervision | Paediatric pulmonologist/intensivist only |
Statement: Not recommended below 6 months of age except under specialist supervision in tertiary care settings.
Safety Monitoring (All Paediatric Patients):
- Heart rate monitoring during acute nebulisation
- Watch for tremor, irritability, vomiting
- Assess frequency of reliever use — indicates control status
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild to moderate impairment | No dose adjustment required |
| Severe impairment (eGFR <30) | Use with caution; limited clearance data — monitor for systemic effects |
| Haemodialysis | Not significantly dialysed; no supplemental dose needed |
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | Use with caution; monitor for systemic adverse effects (tremor, tachycardia) |
| Severe impairment | Use only under specialist supervision; prefer inhaled over oral route |
CONTRAINDICATIONS
- Known hypersensitivity to levosalbutamol, salbutamol, or any β2-agonist
- Severe uncontrolled tachyarrhythmias (e.g., ventricular tachycardia, uncontrolled atrial fibrillation)
- Hypertrophic obstructive cardiomyopathy
- Concurrent use with non-selective beta-blockers (relative — may antagonise effect)
CAUTIONS
- Cardiovascular disease (coronary artery disease, arrhythmias, hypertension) — may exacerbate tachycardia
- Diabetes mellitus — may cause transient hyperglycaemia
- Hyperthyroidism — augmented sympathomimetic response
- Pre-existing hypokalaemia — risk of worsening; correct before or during therapy
- Seizure disorders — may lower seizure threshold at high doses
- Concomitant use with other sympathomimetics — additive cardiovascular effects
- Overuse/dependence — frequent use indicates poor disease control; reassess therapy
PREGNANCY
| Parameter | Details |
| Safety | Generally considered safe; no documented teratogenicity at therapeutic doses |
| Preferred route | Inhaled levosalbutamol or salbutamol preferred over oral/systemic route |
| When to use | For acute bronchospasm or as-needed reliever in pregnant asthmatics |
| Monitoring | Maternal heart rate, blood pressure; uterine activity (high doses may cause tocolysis); avoid excessive use near term |
LACTATION
| Parameter | Details |
| Compatibility | Compatible with breastfeeding |
| Drug levels in milk | Negligible with inhaled route; low with oral route |
| Preferred route | Inhaled administration preferred |
| Infant monitoring | Watch for tremors, irritability, poor feeding if mother on high-dose oral therapy |
ELDERLY
| Parameter | Recommendation |
| Starting dose | Use lowest effective dose; prefer inhaled route |
| Titration | Slower titration if oral route used |
| Special risks | Higher susceptibility to tachycardia, arrhythmias, tremor, hypokalaemia |
| Monitoring | Heart rate, blood pressure, serum potassium (especially with concurrent diuretics/corticosteroids) |
| Comorbidities | Assess for cardiac disease, renal impairment before initiation |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
| Non-selective beta-blockers (propranolol, carvedilol) | Antagonism of bronchodilator effect; may precipitate bronchospasm | Avoid concurrent use; use cardioselective beta-blocker if essential |
| Monoamine oxidase inhibitors (MAOIs) | Risk of severe hypertensive crisis | Avoid use within 14 days of MAOI therapy |
| Tricyclic antidepressants | Potentiation of cardiovascular effects | Use with caution; monitor heart rate and BP |
| Digoxin | SABA may reduce serum digoxin levels via potassium shift | Monitor digoxin levels and serum potassium |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
| Loop diuretics (furosemide), Thiazides | Additive hypokalaemia | Monitor serum potassium; supplement if needed |
| Systemic corticosteroids | Enhanced hypokalaemia risk | Monitor potassium, especially with high-dose steroids |
| Theophylline/Aminophylline | Additive cardiac and CNS stimulation | Use with caution; monitor for toxicity signs |
| Other sympathomimetics (epinephrine, pseudoephedrine) | Additive cardiovascular effects | Avoid or use cautiously |
| QT-prolonging drugs | Hypokalaemia may increase arrhythmia risk | Monitor ECG and electrolytes |
COMMON ADVERSE EFFECTS
- Tremor (dose-related, most common)
- Palpitations
- Tachycardia
- Headache
- Nervousness/anxiety
- Throat irritation or dryness (inhaled route)
- Nausea (oral route)
- Muscle cramps
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Action |
| Paradoxical bronchospasm | Discontinue immediately; administer alternative bronchodilator; do not rechallenge |
| Severe hypokalaemia | Monitor ECG; replace potassium; can precipitate arrhythmias |
| Cardiac arrhythmias (SVT, VT) | Discontinue; cardiac monitoring; treat arrhythmia as indicated |
| Hypersensitivity reactions (urticaria, angioedema) | Discontinue; supportive care |
| Lactic acidosis (rare, with high-dose IV use) | Supportive management |
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | Heart rate, blood pressure, serum potassium (if high-dose or oral use anticipated), baseline SpO₂ |
| After initiation | Symptom response; heart rate after first few doses |
| Long-term | Frequency of SABA use (indicator of control); inhaler technique review at each visit; serum potassium if on concurrent diuretics/steroids; reassess asthma control regularly |
BRANDS AVAILABLE IN INDIA
| Brand Name | Manufacturer | Formulation |
| Levolin | Cipla | MDI, Respules, Syrup, Tablets |
| Salbair-L | Lupin | Respules |
| Levosiz | Zydus | MDI, Respules |
| Asthalin-L | IPCA | MDI |
| L-Salbutamol | Various | Tablets, Syrup |
Fixed-Dose Combinations (FDCs):
| Brand Name | Composition | Manufacturer |
| Duolin | Levosalbutamol + Ipratropium | Cipla |
| Combimist-L | Levosalbutamol + Ipratropium | Zydus |
PRICE RANGE (INR)
| Formulation | Approximate Price |
| MDI 50 mcg (200 doses) | ₹100–150 |
| Respules 0.63 mg (unit dose) | ₹8–12 per vial |
| Respules 1.25 mg (unit dose) | ₹10–15 per vial |
| Tablets 1 mg (strip of 10) | ₹15–25 |
| Syrup 100 mL | ₹30–50 |
- Salbutamol (racemic) is included under NLEM; levosalbutamol pricing is not NPPA-controlled
- Available in government supply as salbutamol; levosalbutamol primarily in private sector
CLINICAL PEARLS
- Levosalbutamol vs Salbutamol: Levosalbutamol is the R-enantiomer (active form) of racemic salbutamol; theoretical advantage of fewer side effects, but clinical superiority remains inconsistent — choice often based on tolerability and cost
- MDI + Spacer Preferred: For most age groups, MDI with spacer is as effective as nebulisation and more practical for outpatient use; nebulisation reserved for severe exacerbations or very young children
- SABA Overuse Alert: If patient requires SABA >2 times/week (excluding pre-exercise use), indicates poor asthma control — step-up controller therapy
- Never Monotherapy in Persistent Asthma: SABA should always be combined with ICS in persistent asthma; SABA-only treatment increases exacerbation and mortality risk
- Pregnancy Safe: Inhaled SABA is safe and preferred for managing asthma during pregnancy; uncontrolled asthma poses greater risk to mother and fetus than medication
- Hypokalaemia Monitoring: In patients on concurrent diuretics, high-dose steroids, or receiving frequent nebulisations, monitor serum potassium regularly
TAGS
levosalbutamol; bronchodilator; SABA; asthma; COPD; acute bronchospasm; paediatric-safe; pregnancy-safe; inhaler; nebulisation; pulmonology
VERSION
RxIndia v0.1 — 19 Feb 2026
REFERENCES
- CDSCO approved product information
- Indian Pharmacopoeia / National Formulary of India
- NLEM India (reference for salbutamol)
- IAP Asthma Guidelines
- AIIMS Paediatric Treatment Protocols
- API Textbook of Medicine
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.